Light-based technologies for management of COVID-19 pandemic crisis.
Autor: | Sabino CP; Department of Clinical Analysis, Faculty of Pharmaceutical Sciences, University of São Paulo, SP, Brazil; BioLambda, Scientific and Commercial LTD, São Paulo, SP, Brazil. Electronic address: caetano@biolambda.com., Ball AR; GAMA Therapeutics LLC, Massachusetts Biomedical Initiatives, Worcester, USA., Baptista MS; Department of Biochemistry, Institute of Chemistry, University of São Paulo, São Paulo, SP, Brazil.. Electronic address: baptista@iq.usp.br., Dai T; Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Vaccine and Immunotherapy Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Hamblin MR; Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Laser Research Centre, Faculty of Health Science, University of Johannesburg, Doornfontein, South Africa., Ribeiro MS; Center for Lasers and Applications, Nuclear, and Energy Research Institute, National Commission for Nuclear Energy, São Paulo, SP, Brazil., Santos AL; GAMA Therapeutics LLC, Massachusetts Biomedical Initiatives, Worcester, USA; Department of Chemistry Rice University, Houston, TX, USA; IdISBA - Fundación de Investigación Sanitaria de las Islas Baleares, Palma, Spain., Sellera FP; Department of Internal Medicine, School of Veterinary Medicine and Animal Science, University of São Paulo, São Paulo, SP, Brazil; School of Veterinary Medicine, Metropolitan University of Santos, Santos, Brazil., Tegos GP; GAMA Therapeutics LLC, Massachusetts Biomedical Initiatives, Worcester, USA; Micromoria LLC, Marlborough, USA., Wainwright M; School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK. |
---|---|
Jazyk: | angličtina |
Zdroj: | Journal of photochemistry and photobiology. B, Biology [J Photochem Photobiol B] 2020 Nov; Vol. 212, pp. 111999. Date of Electronic Publication: 2020 Aug 19. |
DOI: | 10.1016/j.jphotobiol.2020.111999 |
Abstrakt: | The global dissemination of the novel coronavirus disease (COVID-19) has accelerated the need for the implementation of effective antimicrobial strategies to target the causative agent SARS-CoV-2. Light-based technologies have a demonstrable broad range of activity over standard chemotherapeutic antimicrobials and conventional disinfectants, negligible emergence of resistance, and the capability to modulate the host immune response. This perspective article identifies the benefits, challenges, and pitfalls of repurposing light-based strategies to combat the emergence of COVID-19 pandemic. (Copyright © 2020 Elsevier B.V. All rights reserved.) |
Databáze: | MEDLINE |
Externí odkaz: |